Free press releases distribution network?

Agency / Source: Royal DSM N.V.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



DSM Completes Acquisition of Cargillís Cultures and Enzymes Business - Royal DSM, the global Life Sciences and Materials Sciences company, announced today that it has successfully completed the acquisition of Cargillís cultures and enzymes business - DSM.com
DSM Completes Acquisition of Cargillís Cultures and Enzymes Business

 

PRZOOM - /newswire/ - Heerlen, NL, United States, 2012/12/06 - Royal DSM, the global Life Sciences and Materials Sciences company, announced today that it has successfully completed the acquisition of Cargillís cultures and enzymes business - DSM.com. Euronext: DSM KON

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The acquisition, announced on 26 October 2012, will enable DSM to become a global tier one dairy ingredients supplier.

A variety of cheeses on a cheese board
The cultures and enzymes business of Cargill is a global leading manufacturer of cultures and enzymes for the dairy and meat industries with manufacturing operations in Wisconsin (USA) and France. It has a strong pipeline of new products built on three pillars of technology: culture texture toolbox, fast acidification for cheese yield improvements and culture flavor systems. The business generates net sales of about Ä45 million per year with approximately 200 employees.

The market for cultures and enzymes is valued at over Ä1 billion, growing steadily at more than 5% per annum. Applications are primarily found in dairy products which continue to have a healthy and tasty appeal to consumers worldwide. The growing diversity of dairy products requires versatile culture offerings enhancing taste, texture and mouth feel characteristics as well as health benefits (lower fat, less sugar, etc.) and convenience.

By combining Cargillís cultures and enzymes business with the dairy business of DSM Food Specialties, a strong global player will be created, enabling DSM to accelerate sales and capture meaningful synergies in global manufacturing and customer reach as well as innovation capabilities in biotechnology and SG&A.

The combination of the two businesses will allow DSM to achieve its ambition to become a tier one supplier of cultures and enzymes to the global dairy market and will greatly accelerate DSMís growth plans for its business, which continues to benefit from strong consumer demand for more versatile dairy products. The acquisition further strengthens DSMís global position in dairy ingredients with enzymes, PUFAs, vitamins, cultures, probiotics, bio actives, preservation systems and tests.

DSM Investor Relations
Dave Huizing
T: +31 (0)45 578 2864 - E: investor.relations[.]dsm.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Royal DSM N.V.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


DSM Completes Acquisition of Cargillís Cultures and Enzymes Business

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Royal DSM N.V. |
Contact: Herman Betten - DSM.com 
+31(0)45 5782017 media.relations[.]dsm.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Royal DSM N.V. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Royal DSM N.V. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsenís Somatulineģ Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentechís Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com

Visit  SKS Media | SKS Associates Ltd







 
  ©2017 PRZOOM ó Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today